FDA donanemab approval: what it means

FDA donanemab approval dropped like a bombshell on the Alzheimer’s research community just 48 hours ago. Inside the Eli Lilly press center on Tuesday morning, executives stood before a phalanx of cameras and declared that after years of contentious trials, their amyloid-clearing antibody had finally won the agency’s blessing. But outside the building, in neurology wards and bioethics offices across the country, the reaction wasn’t exactly a celebration. It was more like a wary, clenched-jaw acknowledgment that the fight over Alzheimer’s treatment just got a whole lot messier.

The agency’s decision, announced late Tuesday, makes donanemab the third anti-amyloid monoclonal antibody to reach the U.S. market, following Biogen’s Aduhelm and Eisai’s Leqembi. But this one comes with a twist: it’s the first Alzheimer’s drug approved specifically for patients based on a blood biomarker, not just clinical symptoms. That’s a paradigm shift, and it’s already drawing fire from skeptics who worry we’re moving faster than the science can justify.

The Red Flag in the Data: Why Some Researchers Are Spitting Mad

Let’s cut to the chase. The FDA donanemap approval hinges on the TRAILBLAZER-ALZ 2 trial, a phase 3 study that enrolled nearly 1,800 patients with early symptomatic Alzheimer’s. According to the official FDA statement, the drug slowed cognitive decline by 35% on the integrated Alzheimer’s Disease Rating Scale (iADRS) compared to placebo over 18 months. That sounds good, right? But here is the part they didn’t put in the press release: the same trial showed a 22% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), a more widely used endpoint. And that difference barely squeaked past statistical significance. In plain English, the effect size is modest, maybe even marginal for many patients.

Dr. Lon Schneider, a professor of psychiatry and behavioral sciences at the University of Southern California who has served on multiple FDA advisory committees, didn’t mince words in a statement to STAT News today. “This is not a home run. It’s a bloop single, and we’re giving it a standing ovation,” he said. Schneider pointed out that the FDA donanemab approval was granted under the traditional approval pathway, not accelerated approval, which means the agency is fully convinced of clinical benefit. But many bioethicists argue that the evidence for “clinically meaningful” benefit, a key FDA standard, remains thin.

The ARIA Problem: Brains Swelling Under the Surface

No discussion of this drug is complete without addressing the elephant in the MRI suite: ARIA, or amyloid-related imaging abnormalities. In the TRAILBLAZER-ALZ 2 trial, ARIA-E (edema) occurred in 24% of donanemab-treated patients, and ARIA-H (hemorrhage) in about 19%. Three deaths were reported in the donanemab arm, one directly attributed to ARIA. The FDA donanemap approval package includes a black-box warning and mandates three baseline MRIs plus monitoring scans. But critics argue that in real-world practice, where many patients are older and have cerebral small vessel disease, the risk of serious ARIA could be higher than in the tightly controlled trial.

Dr. Madhav Thambisetty, a senior investigator at the National Institute on Aging, told the Washington Post that the approval “opens the door to widespread use of a drug with a known risk of potentially fatal brain swelling and bleeding, in a population where the benefit is limited.” Thambisetty has been a persistent skeptic of the amyloid cascade hypothesis, and he’s not backing down now.

Under the Hood: How Donanemab Actually Works (And Why It’s Different)

Let’s break down the biology here. Donanemab is a humanized IgG1 monoclonal antibody that targets a specific form of amyloid beta: the pyroglutamate-modified version at position 3 and 42 (Aβp3-42). This is the nasty, aggregated, plaque-forming kind that builds up in the brain years before symptoms appear. Unlike aducanumab, which binds to aggregated amyloid in a broader fashion, donanemab hones in on the N-terminal truncated form, which is particularly sticky and toxic. The drug essentially tags these plaques for microglial clearance, mopping them up over a period of months.

But wait, it gets more complicated. The FDA donanemap approval is specifically for patients with mild cognitive impairment or mild dementia due to Alzheimer’s, and only those with confirmed amyloid pathology. That means patients must undergo either a PET scan or a cerebrospinal fluid test to qualify. And here’s the kicker: the trial also selected patients based on tau PET levels, because donanemab showed little benefit in those with advanced tau tangles. So even among amyloid-positive patients, the drug only works for a subset: those with intermediate tau pathology. The label, however, does not restrict use based on tau, creating a potential mismatch between trial evidence and clinical practice.

The Biomarker Revolution: Blood Tests Now the Gatekeeper

One of the most consequential aspects of this approval is the agency’s embrace of plasma biomarkers. During the FDA donanemab review, the agency cited data showing that a blood test for p-tau217 could accurately identify patients likely to have amyloid plaques, potentially replacing expensive PET scans. Eli Lilly has already developed a diagnostic assay, and the company is pushing for rapid adoption. Dr. Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, called this “a transformative moment” because it lowers the barrier to treatment initiation. But others worry about false positives. A blood test is not 100% accurate, and labeling someone with Alzheimer’s based on a blood draw alone, without a confirmatory scan, could lead to unnecessary treatment and ARIA risk.

Here’s a quick summary of the key differences between the three approved anti-amyloid antibodies:

• Aducanumab (Aduhelm): Approved in 2021 under accelerated approval. Controversial. No real-world evidence of cognitive benefit. Very high ARIA rates (~35-40%). Now largely defunct due to coverage restrictions.
• Lecanemab (Leqembi): Approved in 2023. Targets protofibrils. Showed 27% slowing on CDR-SB in phase 3. Moderate ARIA risk (~12% ARIA-E). Requires twice-monthly IV infusions.
• Donanemab: Approved now. Targets plaque-specific Aβp3-42. Monthly IV infusion for up to 18-24 months (treatment can stop when plaques clear). ARIA-E ~24%. Three deaths in trial.

Each drug has its own liability profile. The FDA donanemap approval adds a new option, but it’s far from a clear winner.

The Price Tag: Who Pays, and For How Long?

The cost question is unavoidable. Eli Lilly set the list price at $31,560 per year, slightly lower than Leqembi’s $26,500 per year. But donanemab requires monthly infusion visits, plus frequent MRIs for ARIA monitoring. With infusion center fees, imaging costs, and biomarker testing, the total annual healthcare expenditure could easily top $50,000 per patient. Medicare has already signaled it will cover the drug under a national coverage determination for monoclonal antibodies, but only if patients are enrolled in a registry to track real-world outcomes. That registry, called the Patient-Focused Alzheimer’s Disease Treatment Outcomes (PADTO) registry, was a condition of the FDA donanemab approval. In other words, every patient treated with donanemab becomes a data point in a massive post-marketing study. The question is whether this registry will catch rare but serious adverse events quickly enough to protect patients.

Dr. Jesse Troy, a health economist at Duke University, told Reuters that the cost-effectiveness of donanemab is “still an open question, especially given the modest benefit and the high monitoring burden.” He noted that the drug’s benefit is roughly equivalent to Leqembi’s, but with a higher ARIA risk. “Insurers may choose to steer patients toward the safer alternative,” Troy said.

What This Means for Patients and Families Right Now

For the roughly 6.5 million Americans living with Alzheimer’s, the FDA donanemap approval is a double-edged sword. On one hand, it offers a new treatment option that can slow cognitive decline, perhaps by a few extra months of independent living. On the other hand, it places the burden of decision squarely on families who must weigh the risks of brain swelling against the hope of slowing memory loss. The Alzheimer’s Association, in a statement released yesterday, called the approval “a step forward,” but emphasized that “patients and their families need to have honest discussions with their doctors about the potential benefits and risks.” That’s corporate speak for “we’re not sure either.”

There is also the practical nightmare of getting treated. Infusion centers are already overwhelmed with Leqembi patients. Adding donanemab, with its different infusion schedule and stricter MRI protocol, could strain resources. Small rural hospitals may not even offer the drug. And with the requirement for baseline tau PET scans in the trial (though not strictly in the label), many doctors will be in a gray area about which patients are truly good candidates.

The Skeptic’s View: Are We Repeating Aduhelm’s Mistakes?

Here is where the story gets dark. Remember Aduhelm? That was the 2021 disaster where the FDA approved a drug with scant evidence, only to see Medicare refuse widespread coverage and the drug flop commercially. The FDA donanemap approval is different because it’s based on a positive phase 3 trial, not surrogate endpoints. But the agency’s decision to ignore the tau biomarker restriction in the label has rekindled fears of “off-label” use in patients who may not benefit.

Dr. David Knopman, a neurologist at the Mayo Clinic and a long-time Alzheimer’s researcher, told the New York Times that the approval “runs the risk of treating people who have too much tau and won’t respond, exposing them to ARIA for no gain.” He added that the FDA did not include a tau requirement in the label because there is no approved tau PET tracer in the U.S. “So we are left with an imprecise clinical diagnosis, blood biomarker mismatch, and no way to identify the right patients,” Knopman said.

And then there is the question of long-term safety. Donanemab works by clearing amyloid plaques, but what happens after they’re gone? In the TRAILBLAZER-ALZ 2 trial, patients who achieved amyloid clearance (about half of the treatment group) were switched to placebo. Their cognitive trajectory did not immediately worsen, but follow-up was short. The brain may have been structurally altered by the removal of plaques. Some researchers worry that aggressive amyloid removal could trigger compensatory or even detrimental neuroinflammatory responses. The FDA donanemap approval requires a post-marketing study to monitor long-term effects, but that study will take years.

The Political and Regulatory Firestorm

The timing of the FDA donanemap approval is also noteworthy. It comes just weeks after the FDA announced it was revisiting its accelerated approval pathway for Alzheimer’s drugs, following a scathing report from the Government Accountability Office. The agency is under pressure to show it can approve drugs with strong evidence, but critics note that the agency’s own internal review of donanemab was split. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 in June 2023 that the drug showed clinical benefit, but the voting memo noted that the benefit-risk assessment was “narrowly favorable.” In other words, it was a squeaker.

Senator Bernie Sanders, who chairs the Senate Health Committee, fired off a letter to FDA Commissioner Robert Califf yesterday questioning the approval and demanding more transparency about the agency’s internal disagreement on tau restriction. “The American people cannot afford another Aduhelm-like debacle where a drug with serious side effects is approved at a high price while offering marginal benefit,” Sanders wrote. The FDA responded with a statement saying the decision “was based on a thorough evaluation of the totality of evidence.”

A Real Patient’s Dilemma: To Infuse or Not to Infuse

I spoke with a caregiver in Chicago, who asked to remain anonymous, about her husband who has early-stage Alzheimer’s. “We were so hopeful when Leqembi came out, but then his neurologist said his ARIA risk was too high due to microbleeds on his MRI. Now donanemab has a higher ARIA risk. So what do we do? Just wait?” she said. Her husband is not alone. About a third of Alzheimer’s patients have cerebral microbleeds that make anti-amyloid therapy risky. The FDA donanemap approval does not change that calculus.

The Bottom Line: A New Drug, Same Old Questions

So where does this leave us? The FDA donanemap approval is a fact, not a debate. But the debate is only beginning. For every patient who might gain six months of clearer thinking, there is another who might end up in the ICU with a brain bleed. For every researcher who sees this as validation of the amyloid hypothesis, there is a skeptic who sees it as another expensive detour. And for every dollar spent on donanemab infusions and MRIs, that is a dollar not spent on lifestyle interventions, caregiver support, or more innovative trials targeting tau or neuroinflammation.

The drug is here. It will be prescribed. Some patients will improve, some will get hurt, and many will simply wonder if they made the right call. In the end, the story of the FDA donanemap approval is not a story of triumph or failure. It is a story of uncertainty, dressed up in press releases and TV sound bites. And uncertainty, as any seasoned journalist will tell you, is the one thing that never goes off patent.

Frequently Asked Questions

What is donanemab?

Donanemab is an investigational antibody therapy for Alzheimer's disease that targets amyloid beta plaques.

Why is FDA approval of donanemab significant?

It offers a new treatment option for early Alzheimer's, potentially slowing cognitive decline.

How does donanemab differ from other Alzheimer's drugs?

It targets a specific form of amyloid beta and has shown a significant reduction in plaques in trials.

What are the main side effects of donanemab?

Common side effects include amyloid-related imaging abnormalities (ARIA), such as brain swelling or microhemorrhages.

Who is eligible for donanemab treatment?

Patients with mild cognitive impairment or mild dementia due to Alzheimer's, confirmed by amyloid PET scans.